In a study on EPO as a treatment option for memory impairment in neuropsychiatric diseases, recombinant human EPO could consistently improve memory and cognition in patients with multiple sclerosis, schizophrenia, major depression, and bipolar disorder7,33,35–37. The gene discussed is EPO; the disease is major depressive disorder.